Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 1
1992 1
1994 2
1995 2
1999 1
2000 2
2001 2
2003 1
2004 1
2005 2
2006 2
2007 1
2008 1
2009 4
2010 6
2011 4
2012 5
2013 2
2014 3
2015 4
2016 3
2017 7
2018 10
2019 13
2020 15
2021 17
2022 11
2023 13
2024 6
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Trigo J, et al. Among authors: olmedo me. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. Lancet Oncol. 2020. PMID: 32224306 Clinical Trial.
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohé C, Farago AF, López-Vilariño JA, Cullell-Young M, Nieto A, Vasco N, Gómez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sánchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Dómine M, Paz-Ares L. Aix SP, et al. Among authors: olmedo me. Lancet Respir Med. 2023 Jan;11(1):74-86. doi: 10.1016/S2213-2600(22)00309-5. Epub 2022 Oct 14. Lancet Respir Med. 2023. PMID: 36252599 Clinical Trial.
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A, Rodríguez-Remírez M, López I, Macaya I, Guruceaga E, Olmedo M, Vilalta-Lacarra A, Welch C, Sandiego S, Vicent S, Valencia K, Calvo A, Pio R, Raez LE, Rolfo C, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: olmedo m. Mol Cancer. 2024 Apr 20;23(1):78. doi: 10.1186/s12943-024-01991-3. Mol Cancer. 2024. PMID: 38643157 Free PMC article.
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
Dowlati A, Hummel HD, Champiat S, Olmedo ME, Boyer M, He K, Steeghs N, Izumi H, Johnson ML, Yoshida T, Bouchaab H, Borghaei H, Felip E, Jost PJ, Gadgeel S, Chen X, Yu Y, Martinez P, Parkes A, Paz-Ares L. Dowlati A, et al. Among authors: olmedo me. J Clin Oncol. 2024 Oct 10;42(29):3392-3399. doi: 10.1200/JCO.24.00553. Epub 2024 Aug 29. J Clin Oncol. 2024. PMID: 39208379 Free PMC article. Clinical Trial.
Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci.
Escrihuela-Vidal F, Berbel D, Fernández-Hidalgo N, Escolà-Vergé L, Muñoz P, Olmedo M, Goenaga MÁ, Goikoetxea J, Fariñas MC, De Alarcón A, Miró JM, Ojeda G, Plata A, Cuervo G, Carratalà J; GAMES Investigators. Escrihuela-Vidal F, et al. Among authors: olmedo m. Clin Infect Dis. 2023 Nov 11;77(9):1273-1281. doi: 10.1093/cid/ciad375. Clin Infect Dis. 2023. PMID: 37345869
Treating KRAS-mutant NSCLC: latest evidence and clinical consequences.
Garrido P, Olmedo ME, Gómez A, Paz Ares L, López-Ríos F, Rosa-Rosa JM, Palacios J. Garrido P, et al. Among authors: olmedo me. Ther Adv Med Oncol. 2017 Sep;9(9):589-597. doi: 10.1177/1758834017719829. Epub 2017 Jul 24. Ther Adv Med Oncol. 2017. PMID: 29081842 Free PMC article. Review.
Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes.
García-Goñi M, Vázquez Gutiérrez B, Sanmamed MF, Martín-Algarra S, Luis Pérez-Gracia J, Olmedo M, Chumbiauca E, Martín-Calvo N, Galofré JC. García-Goñi M, et al. Among authors: olmedo m. Endocr Relat Cancer. 2024 Aug 8;31(10):e240064. doi: 10.1530/ERC-24-0064. Print 2024 Oct 1. Endocr Relat Cancer. 2024. PMID: 39013402
Aging during C. elegans L1 quiescence.
Mata-Cabana A, Romero-Expósito FJ, Olmedo M. Mata-Cabana A, et al. Among authors: olmedo m. Aging (Albany NY). 2020 Sep 27;12(18):17756-17758. doi: 10.18632/aging.104027. Epub 2020 Sep 27. Aging (Albany NY). 2020. PMID: 32986012 Free PMC article. No abstract available.
127 results